Articles related to GLYCEMIC CONTROL

The invention of plant-based oral insulin, which provides a more secure and efficient substitute for insulin injections, marks a significant advancement in the management of diabetes. Investigate this ground-breaking strategy that could revolutionize accessibility to diabetes treatment worldwide.

The World Health Organization advises against nonsugar sweeteners for weight control, citing potential long-term risks such as type 2 diabetes and cardiovascular diseases. Instead, reducing free sugars and opting for natural sweetness sources is recommended to enhance dietary quality.

The Diabetes Plate Method streamlines meal planning for diabetes management. Utilizing a 9-inch plate, it divides meal components into nonstarchy vegetables, lean proteins, and carbohydrates. An efficient tool for physicians to guide patient dietary habits effectively.

Let’s delve into the groundbreaking application of endoscopic electroporation and semaglutide that’s changing the game in diabetes management. First off, the EMINENT study is unveiling a revolutionary approach in treating type 2 diabetes. This method combines endoscopic electroporation, known as ReCET, with the medication semaglutide. The main goal is to reduce or potentially eliminate the need for insulin, revolutionizing glycemic control. The innovative ReCET procedure employs electroporation to ablate the superficial layer of mucosa in the small intestine. Researchers hope that by rejuvenating the duodenal lining and employing a GLP-1 receptor agonist, they could address insulin resistance, the fundamental problem in type 2 diabetes. Interestingly, ReCET doesn’t use extreme temperatures to ablate intestinal tissue. Rather, it uses a pulsed electric field, yielding precise control and limited depth of penetration. This method disrupts the cellular membrane of the mucosa and superficial submucosa, triggering natural cell death within a day, thereby significantly minimizing the risk of complications. A single-arm pilot study conducted as part of EMINENT involved 14 patients with type 2 diabetes using long-acting basal insulin. All patients underwent the ReCET procedure and started on semaglutide two weeks later. Researchers noted the feasibility and safety of ReCET, with a 100% success […]

In a study including 73 meta-analyses and 8,601 unique articles, sugar consumption was associated with 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes. Endocrine/metabolic outcomes included weight gain, ectopic fat accumulation, obesity, and cardiovascular disease, which were largely attributed to excessive consumption of fructose containing sugars.

In a study of patients with DM2, 75 years old and over, continuous glucose monitoring revealed that 65% had glucose level two times below range (<54 mg/dL during ≥15 consecutive minutes) between midnight and 6 a.m. Fewer than half of the patients detected the hypoglycemic episode via self-monitoring. Because hypoglycemia episodes are associated with long-term complications, continuous glucose monitoring (CGM) could be used to improve care in these patients.